Handelsbanken Fonder Ab Vaxcyte, Inc. Transaction History
Handelsbanken Fonder Ab
- $25.3 Billion
- Q3 2024
A detailed history of Handelsbanken Fonder Ab transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 27,100 shares of PCVX stock, worth $2.86 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
27,100
Previous 27,300
0.73%
Holding current value
$2.86 Million
Previous $2.06 Million
50.27%
% of portfolio
0.01%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding PCVX
# of Institutions
290Shares Held
110MCall Options Held
248KPut Options Held
109K-
Black Rock Inc. New York, NY9.94MShares$1.05 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.8MShares$1.03 Billion0.01% of portfolio
-
Janus Henderson Group PLC London, X08.87MShares$936 Million0.37% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.2MShares$866 Million9.34% of portfolio
-
Wellington Management Group LLP Boston, MA4.59MShares$485 Million0.06% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $6.26B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...